Marimed (MRMD) Depreciation & Amortization (CF) (2016 - 2026)

Marimed (MRMD) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 19.15% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 8.69% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 2.52% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MRMD reached as high as $2.2 million in Q4 2024 and fell as low as $702000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.8 million in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 96.55% in 2024 and declined 6.76% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $963000.0 in 2022, then soared by 77.67% to $1.7 million in 2023, then advanced by 26.3% to $2.2 million in 2024, then fell by 4.07% to $2.1 million in 2025, then advanced by 3.86% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.1 million in Q3 2025.